Let us remember this was for Multiple Myloma low dose testing. CLL and Lymphoma are still going strong.
This was also a phase 1/2 test of low dose. It is not that it didn't work, it was not producing the efficacy they had hoped for. It is possible Regular dose will work out fine. PCYC has said they are only discontinuing the low dose test.
It is possible this is a great buying opportunity.
PCI-24871 has shown great promise. Can't wait until December to see the results.